Testing effectiveness (Phase 2)Looking for participantsNCT07252739
What this trial is testing
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
Who this might be right for
Malignant Neoplasm
Merck Sharp & Dohme LLC 130